PriceTargets.com logo

Athenex - ATNX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 05/24/2023 05:00 PM ET
+0 (0.00%)
Get New Athenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATNX

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Athenex in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ATNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Athenex. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2023LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
3/17/2022SVB LeerinkBoost TargetMarket Perform$2.00 ➝ $3.00High
10/12/2021Royal Bank of CanadaLower TargetOutperform$8.00 ➝ $5.00High
8/6/2021Royal Bank of CanadaLower TargetOutperform$9.00 ➝ $8.00Medium
8/6/2021SVB LeerinkLower TargetMarket Perform$5.00 ➝ $4.00High
7/8/2021SVB LeerinkReiterated RatingHoldHigh
7/6/2021OppenheimerReiterated RatingHoldHigh
7/6/2021Needham & Company LLCReiterated RatingHoldHigh
5/9/2021SVB LeerinkReiterated RatingHoldLow
3/9/2021Truist FinancialReiterated RatingBuy ➝ Hold$29.00 ➝ $6.00Low
3/8/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$22.00 ➝ $5.00N/A
3/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$30.00 ➝ $7.00N/A
3/8/2021OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
3/2/2021Royal Bank of CanadaBoost TargetPositive ➝ Outperform$9.00 ➝ $33.00Medium
3/2/2021OppenheimerDowngradeOutperform ➝ Market PerformMedium
3/2/2021Truist FinancialDowngradeBuy ➝ Hold$6.00Medium
3/1/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$22.00 ➝ $5.00High
3/1/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $7.00High
3/1/2021LaidlawLower TargetBuy$38.00 ➝ $13.00Medium
3/1/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
2/10/2021Evercore ISIInitiated CoverageOutperformLow
11/5/2020Needham & Company LLCLower TargetBuy$30.00 ➝ $27.00Medium
10/26/2020SVB LeerinkInitiated CoverageOutperform$22.00Low
9/1/2020Royal Bank of CanadaBoost TargetOutperform$31.00 ➝ $33.00Low
6/22/2020Needham & Company LLCReiterated RatingBuy$30.00Medium
6/7/2020OppenheimerInitiated CoverageBuy$23.00High
5/13/2020OppenheimerReiterated RatingBuy$23.00Medium
5/7/2020OppenheimerReiterated RatingBuy$23.00Low
4/9/2020Needham & Company LLCReiterated RatingBuy$30.00N/A
12/16/2019Needham & Company LLCReiterated RatingBuy$30.00High
12/6/2019SunTrust BanksInitiated CoverageBuy$28.00High
11/19/2019Royal Bank of CanadaReiterated RatingBuy$31.00Medium
7/30/2019SunTrust BanksBoost TargetBuy$30.00Low
6/25/2019Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$29.00 ➝ $31.00Low
5/2/2019CIBCInitiated CoverageOutperform ➝ Outperform$20.00Medium
5/2/2019OppenheimerInitiated CoverageOutperform$20.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Athenex logo
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.95
Low: $0.20
High: $1.52

52 Week Range

Now: N/A

Volume

1,880,200 shs

Average Volume

194,316 shs

Market Capitalization

$1.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Athenex?

The following Wall Street analysts have issued reports on Athenex in the last year:
View the latest analyst ratings for ATNX.

What is the current price target for Athenex?

0 Wall Street analysts have set twelve-month price targets for Athenex in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Athenex in the next year.
View the latest price targets for ATNX.

What is the current consensus analyst rating for Athenex?

Athenex currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ATNX.

What other companies compete with Athenex?

Other companies that are similar to Athenex include PainReform, Galmed Pharmaceuticals, Bio-Path, Lucy Scientific Discovery and InMed Pharmaceuticals. Learn More about companies similar to Athenex.

How do I contact Athenex's investor relations team?

Athenex's physical mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company's listed phone number is (716) 427-2950 and its investor relations email address is [email protected]. The official website for Athenex is www.athenex.com. Learn More about contacing Athenex investor relations.